News - GlaxoSmithKline, Benlysta, epratuzumab

Filter

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData

24-06-2013

Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Epratuzumab and Lupuzor have potential to offer improvements over Benlysta in reducing Lupus disease activity

04-04-2013

US and European rheumatologists surveyed by health care advisory firm Decision Resources indicate that…

Anthera PharmaceuticalsAnti-Arthritics/RheumaticsBenlystaBiotechnologyblisibimodepratuzumabEuropeGlaxoSmithKlineImmunomedicsImmuPharmaLupuzorMarkets & MarketingNorth AmericaPharmaceuticalUCB

Back to top